Clinical Trial Update: Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine [Phase 1]

View source ↗

Summary

Phase 1 study assessing pharmacokinetic interactions between moxifloxacin and rifapentine for tuberculosis, which has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Moxifloxacin (moxifloxacin)
• rifapentine (rifapentine)

Snippet

Sponsor: Johns Hopkins University | Conditions: Mycobacterium Tuberculosis | Phase 1 | Status: TERMINATED